AgingResearch.NewsJoin free

Phase 2RecruitingHealthspan endpoint

DAOIB for the Treatment of Brain Fog

DAOIB for the Treatment of Cognitive Impairment Induced by COVID-19 -An Open Trial

Sponsor
Chang Gung Memorial Hospital (Academic or other)
Enrollment
40 planned
Conditions
Long COVID
Interventions
DAOIB
Ages
adults, older adults
Registry
NCT05764538

Full record on ClinicalTrials.gov

From the registry

This is a 24-week open trial. We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks. We will assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize that DAOIB treatment will be beneficial in improving the cognitive function, mood symptoms, global functioning and quality of life in long-COVID patients with cognitive impairments.

Primary outcomes

  • Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24

History

  1. Primary completion expected

  2. Last registry update

  3. Registered

  4. Started